NOVARTIS AG (NVS)
About NOVARTIS AG
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $284.6B
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $284.6B
- Dividend yield
- 3.06%
- Shares outstanding
- 1.8B
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 7, 1996
Novartis AG (NVS) Stock Price
- Trading 8% below its 52-week high.
- Pays a dividend yielding about 3.06% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review NOVARTIS AG.
Write a review
News about NOVARTIS AG
News & sentiment via Polygon.io
Novartis AG: frequently asked questions
Is Novartis AG an American company?
Novartis AG is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Novartis AG publicly traded?
Yes — Novartis AG is a publicly traded company. Its stock trades under the ticker symbol NVS on the NYSE.
What does Novartis AG do?
Novartis AG is an American Pharmaceuticals company in the Health & Beauty sector.
When was Novartis AG founded?
Novartis AG was founded in 1996.
